Clinical trial registry record

Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 1, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05758246
Last registry update
September 1, 2026
Status
Recruiting
Phase
Phase 2
Sponsor
University of Minnesota
Enrollment
220
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
220
Population
ALL · 65 Years
Duration
2023-08-23 to 2027-06-30
Intervention
Fisetin-dose 1; Fisetin-dose 2; Placebo
Comparator
Placebo
Outcomes measured
Difference in the composite cardiovascular, respiratory, and renal sequential organ failure assessment (CRR-SOFA) — day…; Safety of 2 doses of fisetin in patients with mild sepsis — day 28; Organ failure free days — day 28; Total SOFA score — day 7; Zubrod performance status — day 7; SF-12 score — day 7; SF-12 score — day 28; Zubrod performance status — day 28; Days in the ICU — day 28; All-cause mortality — Day 28; Peripheral CD3+ senescent (SnCs) immune cells — day 7; Outcome is the relative expression of p16Ink4a in CD3+ cells. — day 28; TNF-alpha — day 7
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Senolytics · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

senolytics
Read the original source →Export JSON